Patent 11021492 was granted and assigned to Aeovian Pharmaceuticals, Inc. on June, 2021 by the United States Patent and Trademark Office.
Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.